EGFR and type 2 diabetes mellitus: To this end, we analyzed the incidence and hazard ratio for 21,778 patients with NSCLC and T2DM who received EGFR TKI treatment in a population-based cohort study using data from 2004 to 2014 (Supplementary Fig. 1).